Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Scientific reports, 12, Article 6243, S. 6243-1-6243-5

Event: Veröffentlichung

(where): Bochum

(who): Ruhr-Universität Bochum

(when): 2022

Creator: Bertram, Sebastian Johannes
Blazquez-Navarro, Arturo
Seidel, Maximilian
Hölzer, Bodo
Seibert, Felix Sebastian
Doevelaar, Adrian
Rohn, Benjamin Johannes
Zgoura, Panagiota
Witte‑Lack, Alexandra
Skrzypczyk, Sarah
Scholten, David
Kisters, Klaus
Babel, Nina
Westhoff, Timm

URN: urn:nbn:de:hbz:294-103239

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Bertram, Sebastian Johannes
Blazquez-Navarro, Arturo
Seidel, Maximilian
Hölzer, Bodo
Seibert, Felix Sebastian
Doevelaar, Adrian
Rohn, Benjamin Johannes
Zgoura, Panagiota
Witte‑Lack, Alexandra
Skrzypczyk, Sarah
Scholten, David
Kisters, Klaus
Babel, Nina
Westhoff, Timm
Ruhr-Universität Bochum

Time of origin

2022

Other Objects (12)

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Related objects

Reset password